使用左心室辅助装置的乳腺癌患者放射治疗的安全交付:病例报告及文献回顾。

IF 1.7 Q4 ONCOLOGY
Senem Alanyalı, Emre Karaman, Murat Köylü, Ümit Kahraman, Sanem Nalbantgil
{"title":"使用左心室辅助装置的乳腺癌患者放射治疗的安全交付:病例报告及文献回顾。","authors":"Senem Alanyalı, Emre Karaman, Murat Köylü, Ümit Kahraman, Sanem Nalbantgil","doi":"10.4274/ejbh.galenos.2025.2025-3-5","DOIUrl":null,"url":null,"abstract":"<p><p>The increasing use of cardiac artificial devices, such as cardiac implantable electronic devices (CIED) and left ventricular assist devices (LVAD), results in longer life expectancy and thus may eventually coincide with a risk of cancer diagnosis and requirement for radiotherapy. Safe irradiation dose limits are better studied and reported for CIEDs, but data on LVAD irradiation are scarce. We present a case of a patient diagnosed with breast cancer who developed heart failure and was given an LVAD, received appropriate oncological care including chemotherapy, surgery, and, after careful multidisciplinary review, radiotherapy. The patient's right-sided initial stage II (T1N1) disease necessitated radiation treatment to the chest wall and regional lymphatic nodal areas. Meticulous radiotherapy planning and treatment delivery were performed, and daily LVAD performance checks were done. Maximum and mean doses received by the LVAD system were 767 cGy and 227 cGy, respectively, for the whole treatment period (5000 cGy/25 fractions). During radiotherapy and after 41 months of follow-up, no VLAD malfunction was observed. As this case shows, having an LVAD does not appear to be a contraindication for radiotherapy delivery. Possible risks and consequences should be evaluated in a multidisciplinary setting.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"379-383"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462717/pdf/","citationCount":"0","resultStr":"{\"title\":\"Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature.\",\"authors\":\"Senem Alanyalı, Emre Karaman, Murat Köylü, Ümit Kahraman, Sanem Nalbantgil\",\"doi\":\"10.4274/ejbh.galenos.2025.2025-3-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The increasing use of cardiac artificial devices, such as cardiac implantable electronic devices (CIED) and left ventricular assist devices (LVAD), results in longer life expectancy and thus may eventually coincide with a risk of cancer diagnosis and requirement for radiotherapy. Safe irradiation dose limits are better studied and reported for CIEDs, but data on LVAD irradiation are scarce. We present a case of a patient diagnosed with breast cancer who developed heart failure and was given an LVAD, received appropriate oncological care including chemotherapy, surgery, and, after careful multidisciplinary review, radiotherapy. The patient's right-sided initial stage II (T1N1) disease necessitated radiation treatment to the chest wall and regional lymphatic nodal areas. Meticulous radiotherapy planning and treatment delivery were performed, and daily LVAD performance checks were done. Maximum and mean doses received by the LVAD system were 767 cGy and 227 cGy, respectively, for the whole treatment period (5000 cGy/25 fractions). During radiotherapy and after 41 months of follow-up, no VLAD malfunction was observed. As this case shows, having an LVAD does not appear to be a contraindication for radiotherapy delivery. Possible risks and consequences should be evaluated in a multidisciplinary setting.</p>\",\"PeriodicalId\":93996,\"journal\":{\"name\":\"European journal of breast health\",\"volume\":\" \",\"pages\":\"379-383\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462717/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of breast health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/ejbh.galenos.2025.2025-3-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of breast health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/ejbh.galenos.2025.2025-3-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

心脏人工装置的使用越来越多,如心脏植入式电子装置(CIED)和左心室辅助装置(LVAD),导致预期寿命更长,因此最终可能与癌症诊断的风险和放射治疗的要求相吻合。cied的安全辐照剂量限值得到了更好的研究和报道,但LVAD辐照的数据很少。我们报告了一例被诊断为乳腺癌的患者,她出现了心力衰竭,并给予了左心室辅助装置,接受了适当的肿瘤治疗,包括化疗、手术,并在仔细的多学科审查后,进行了放疗。患者的右侧初始II期(T1N1)疾病需要对胸壁和局部淋巴结进行放射治疗。进行了细致的放疗计划和治疗交付,并进行了每日LVAD性能检查。在整个治疗期间,LVAD系统接受的最大剂量和平均剂量分别为767 cGy和227 cGy (5000 cGy/25份)。放疗期间及随访41个月,未见VLAD功能障碍。正如这个病例所显示的,有左室辅助装置似乎并不是放射治疗的禁忌症。可能的风险和后果应在多学科背景下进行评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature.

Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature.

Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature.

Safe Delivery of Radiotherapy for Breast Cancer Patient With Left Ventricular Assist Device: Case Report and Review of the Literature.

The increasing use of cardiac artificial devices, such as cardiac implantable electronic devices (CIED) and left ventricular assist devices (LVAD), results in longer life expectancy and thus may eventually coincide with a risk of cancer diagnosis and requirement for radiotherapy. Safe irradiation dose limits are better studied and reported for CIEDs, but data on LVAD irradiation are scarce. We present a case of a patient diagnosed with breast cancer who developed heart failure and was given an LVAD, received appropriate oncological care including chemotherapy, surgery, and, after careful multidisciplinary review, radiotherapy. The patient's right-sided initial stage II (T1N1) disease necessitated radiation treatment to the chest wall and regional lymphatic nodal areas. Meticulous radiotherapy planning and treatment delivery were performed, and daily LVAD performance checks were done. Maximum and mean doses received by the LVAD system were 767 cGy and 227 cGy, respectively, for the whole treatment period (5000 cGy/25 fractions). During radiotherapy and after 41 months of follow-up, no VLAD malfunction was observed. As this case shows, having an LVAD does not appear to be a contraindication for radiotherapy delivery. Possible risks and consequences should be evaluated in a multidisciplinary setting.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信